Skip to content

Observation on the clinical therapeutic effect of stellate ganglion block

Observation on the clinical therapeutic effect of stellate ganglion block

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083474
Enrollment
Unknown
Registered
2024-04-26
Start date
2024-04-29
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia, migraines, etc

Interventions

SGB:Administer ultrasound-guided stellate ganglion block

Sponsors

Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-70 years old 2. According to the consensus of experts on stellate ganglion block, the disease needs to be diagnosed as: (1) head and face diseases: headache, facial neuritis, facial muscle spasms, peripheral facial nerve paralysis, atypical facial pain, etc; (2) Diseases of neck, shoulder, and upper limbs: neck, shoulder, and arm syndrome, thoracic outlet syndrome, shoulder periarthritis, cervical spondylosis, hyperhidrosis, Raynaud's disease, upper limb arterial embolism, postherpetic neuralgia, phantom limb pain, residual limb pain, etc; (3) Other: allergic rhinitis, sudden deafness, insomnia, premenstrual syndrome, perimenopausal syndrome, refractory dysmenorrhea, complex local pain syndrome, etc 3. NRS score = 6 4. Provide informed consent form

Exclusion criteria

Exclusion criteria: 1. Communication barriers; 2. Clearly diagnosed neurological and psychiatric disorders, such as dementia, Parkinson's syndrome, myasthenia gravis, schizophrenia, epilepsy, etc; 3. Patients with malignant tumors and their cachexia; 4. Local skin infection; 4. Patients undergoing neck vascular surgery, recent history of myocardial infarction, glaucoma, thyroid enlargement, and abnormal cardiac excitation conduction; 5. Pregnancy and lactation period; 6. Severe coagulation dysfunction and cardiopulmonary dysfunction.

Design outcomes

Primary

MeasureTime frame
Numeric Rating Scale;Symptom severity;

Secondary

MeasureTime frame
Short Form-12;Sleep index;Anxiety and Depression;Adverse reactions;

Countries

China

Contacts

Public ContactMeng Chao

Affiliated Hospital of Qingdao University

mengchao1119@126.com+86 186 6180 8786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026